McMaster University

McMaster University

Theodore (Ted) Earl Warkentin

,
MD, BSc(Med), FRCPC, FACP, FRCP (Edin)

Professor, Pathology and Molecular Medicine

Division: Clinical Pathology

Associate Member, Medicine

Hamilton General Hospital, 1-270B
Hamilton, Ontario
905-527-0271 ext. 46140/46139
twarken@mcmaster.ca

Assistant: Maria Adamek

Theodore E. Warkentin

Faculty Biography

Education and Professional Standing

  • FRCP (Edin) 2013
  • FACP (American College of Physicians), 1992
  • FRCPC Hematology, 1988
  • FRCPC Internal Medicine, 1987
  • MD, University of Manitoba 1983

Interests

Research Focus

To characterize the pathophysiology, frequency, clinical presentation, diagnostic testing, and treatment of heparin-induced thrombocytopenia.

To characterize the pathophysiology, frequency, clinical presentation, diagnostic testing, and treatment of bleeding gastrointestinal angiodysplasia associated with cardiovascular disease.

Clinical Focus

Dr. Warkentin’s clinical focus includes:

  • Transfusion Medicine (Regional Director, Transfusion Medicine, Hamilton Regional Laboratory Medicine Program)
  • Inpatient-focused general hematology
    • acquired thrombocytopenia
    • acquired coagulopathy
    • prothrombotic and prohemorrhagic disorders

Academic Interests

Dr. Warkentin is responsible for haematology training of anaesthesia residents.


Team Members

Technologist

Jo-Ann Sheppard

Selected Publications

Articles

  • Warkentin TE. Ischemic limb gangrene with pulses. N Engl J Med 2015; 373 (7): 642-655. 
  • Warkentin TE, et al. Warfarin-induced venous limb ischemia/gangrene complicating cancer: a novel and clinically distinct syndrome. Blood 2015; 126 (4): 486-493.
  • Warkentin TE, Basciano PA, Knopman J, Bernstein RA. Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder. Blood 2014; 123 (23): 3651-3654.
  • Warkentin TE, Sheppard JI. Serological investigation of patients with a previous history of heparin-induced thrombocytopenia who are reexposed to heparin. Blood 2014; 123 (16): 2485-2493.
  • Warkentin TE. Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls. Exp Opin Drug Saf 2014 Jan; 13 (1): 25-43.
  • Siegal DM, Cook RJ, Warkentin TE. Acute hepatic necrosis and ischemic limb necrosis. N Engl J Med 2012; 367 (9): 879-881
  • Warkentin TE. Aspirin for dual prevention of venous and arterial thrombosis. N Engl J Med 2012; 367: 2039-2041
  • Warkentin TE. HITlights: a career perspective on heparin-induced thrombocytopenia. Am J Hematol 2012; 87 (Suppl. 1): S92-S99.
  • Warkentin TE, Greinacher A, Gruel Y, et al. on behalf of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. J Thromb Haemost 2011; 9: 2498-2500.
  • Warkentin TE. How I diagnose and manage heparin-induced thrombocytopenia. Hematology Am Soc Hematol Educ Program 2011; 2011: 143-149.
  • McFarlane A, Warkentin TE, Cartin W. A novel sickling hemoglobinopathy. N Engl J Med 2011; 365: 1548-1549.
  • Warkentin TE, Davidson BL, Büller HR, et al. Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE. Chest 2011; 140: 366-373.
  • Warkentin TE, Cook RJ, Marder VJ, Greinacher A. Anti-PF4/heparin antibody formation post-orthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization. J Thromb Haemost 2010; 8: 504-512.
  • Warkentin TE, Greinacher A. Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes. Expert Opin Drug Saf 2009; 8: 129-144.
  • Warkentin TE, Sheppard JI, Moore JC, Cook RJ, Kelton JG. Studies of the immune response in heparin-induced thrombocytopenia. Blood 2009; 113: 4963-4969
  • Greinacher A, Warkentin TE. Contaminated heparin. N Engl J Med 2008; 359: 1291-1292.
  • Warkentin TE, Makris M, Jay RM, Kelton JG. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am J Med 2008; 121: 632-636.
  • Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133 (6 Suppl.): 340S-380S.
  • Warkentin TE. Drug-induced immune-mediated thrombocytopenia—from purpura to thrombosis. N Engl J Med 2007;356: 891-893.
  • Warkentin TE, Moore JC, Morgan DG. Resolution of bleeding from gastrointestinal angiodysplasia and von Willebrand syndrome type 2A after aortic valve replacement. N Engl J Med 2002; 347: 858-859.
  • Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001; 135: 502-506.
  • Warkentin TE. Venous limb gangrene during warfarin treatment of cancer-associated deep venous thrombosis. Ann Intern Med 2001; 135: 589-593.
  • Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344: 1286-1292.
  • Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.

Book Chapters

  • Warkentin TE. Thrombocytopenia caused by platelet destruction, hypersplenism, or hemodilution. In: Hoffman R, Benz EJ Jr, Silberstein LE, Heslop HE, Weitz JI, Anastasi J, eds. Hematology: Basic Principles and Practice, 6th edn. Philadelphia: Churchill Livingstone Elsevier, 2013: 1895-1912.
  • Warkentin TE. Heparin-induced thrombocytopenia In: Hoffman R, Benz EJ Jr, Silberstein LE, Heslop HE, Weitz JI, Anastasi J, eds. Hematology: Basic Principles and Practice, 6th edn. Philadelphia: Churchill Livingstone Elsevier, 2013: 1913-1924.
  • Warkentin TE, Marder VJ. Overview of complex thrombohemorrhagic problems. In: Marder VJ, Aird WC, Bennett JS, Schulman S, White GC, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 6th edn. Philadelphia: Lippincott Williams & Wilkins, 2013: 1173-1177.
  • Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia. In: Marder VJ, Aird WC, Bennett JS, Schulman S, White GC, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 6th edn. Philadelphia: Lippincott Williams & Wilkins, 2013: 1292-1307.
  • Warkentin TE. Coumarin-induced skin necrosis and venous limb gangrene. In: Marder VJ, Aird WC, Bennett JS, Schulman S, White GC, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 6th edn. Philadelphia: Lippincott Williams & Wilkins, 2013: 1308-1317.
  • Warkentin TE, Warkentin AE. Acquired thrombocytopenia. In: Concise guide to hematology. Schmaier AH, Lazarus HM, eds. Oxford: Blackwell Publishing Ltd, 2012: 154-173.
  • Warkentin TE. Acquired coagulation disorders. In: Warrell DA, Cox TM, Firth JD, eds. Oxford Textbook of Medicine, 5th edn. Oxford: Oxford University Press, 2010: 4531-4546.
  • Warkentin TE. Thrombocytopenia due to platelet destruction and hypersplenism (Chap 140). In: Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Silberstein LE, McGlave P, Heslop H, eds. Hematology: Basic Principles and Practice, 5th edn. Philadelphia: Churchill Livingstone Elsevier, 2009: 2113-2131.

Books

  • Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia, 5th edn. Boca Raton, FL, CRC Press, 2013 (641 pages)
  • Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia, 4th edn. New York, Informa Healthcare USA, 2007.
Valid XHTML 1.0 Transitional Level Double-A conformance, W3C WAI Web Content Accessibility Guidelines 2.0